A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042
NCT ID: NCT06916169
Last Updated: 2025-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
70 participants
INTERVENTIONAL
2025-08-31
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions
NCT06357910
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers
NCT05737082
Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State
NCT07297940
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
NCT07312799
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
NCT04617509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
Period 1: Coadministration of AG23041 and AG23042, Period 2: AG2304
AG2304
AG2304, Single-dose Oral Administration
AG23041 and AG23042
AG23041/AG23042, Single-dose Oral Administration
Sequence B
Period 1: AG2304, Period 2: Coadministration of AG23041 and AG23042
AG2304
AG2304, Single-dose Oral Administration
AG23041 and AG23042
AG23041/AG23042, Single-dose Oral Administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AG2304
AG2304, Single-dose Oral Administration
AG23041 and AG23042
AG23041/AG23042, Single-dose Oral Administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who are deemed eligible based on the screening tests
Exclusion Criteria
* Other exclusions have been applied
19 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ahn-Gook Pharmaceuticals Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AG2304 BE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.